Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
Age
12–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent of parent(s) or legally acceptable representative of subject and child assent, as appropriate obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
Male or female, ages 12 to below 18 years at the time of signing informed consent
BMI equal to or above 95th percentile OR equal to or above 85th percentile (on gender and age-specific growth charts (CDC.gov)) with 1 or more weight related comorbidity (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes
History of at least one self-reported unsuccessful dietary effort to lose weight
\- HbA1c equal to or below 10.0% (86 mmol/mol) as measured by central laboratory at screening
You may not be if
Prepubertal subjects (Tanner stage 1)
History of type 1 diabetes
A self-reported (or by parent(s)/legally acceptable representative where applicable) change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records
Subjects with secondary causes of obesity (i.e., hypothalamic, monogenic or endocrine causes)
For subjects with type 2 diabetes only: Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Clareo Health | A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
